|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global Cancer Statistics, 2012. Ca
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McLaughlin CC, Baptiste MS, Schymura MJ,
Nasca PC and Zdeb MS: Maternal and infant birth characteristics and
hepatoblastoma. Am J Epidemiol. 163:818–828. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trobaugh-Lotrario AD, Meyers RL, O'Neill
AF and Feusner JH: Unresectable hepatoblastoma: Current
perspectives. Hepatic Med. 9:1–6. 2017. View Article : Google Scholar
|
|
5
|
Livraghi T, Mäkisalo H and Line PD:
Treatment options in hepatocellular carcinoma today. Scand J Surg.
100:22–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rodríguez-Hernández A, Navarro-Villarán E,
González R, Pereira S, Soriano-De Castro LB, Sarrias-Giménez A,
Barrera-Pulido L, Álamo-Martínez JM, Serrablo-Requejo A,
Blanco-Fernández G, et al: Regulation of cell death receptor
S-nitrosylation and apoptotic signaling by sorafenib in
hepatoblastoma cells. Redox Biology. 6:174–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shanmugam N, Valamparampil JJ, Scott JX,
Vij M, Narasimhan G, Reddy MS and Rela M: Complete remission of
refractory hepatoblastoma after liver transplantation in a child
with sorafenib monotherapy: A new hope? Pediatric Blood Cancer. Jul
17–2017.(Epub ahead of print). View Article : Google Scholar
|
|
9
|
Dazert E..Colombi M, Boldanova T, Moes S,
Adametz D, Quagliata L, Roth V, Terracciano L, Heim MH, Jenoe P and
Hall MN: Quantitative proteomics and phosphoproteomics on serial
tumor biopsies from a sorafenib-treated HCC patient. Proc Natl Acad
Sci USA. 113:pp. 1381–1386. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galuppo R, Maynard E, Shah M, Daily MF,
Chen C, Spear BT and Gedaly R: Synergistic inhibition of HCC and
liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and
WNT/β-catenin pathways. Anticancer Res. 34:1709–1713.
2014.PubMed/NCBI
|
|
11
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song X, Wang Z, Jin Y, Wang Y and Duan W:
Loss of miR-532-5p in vitro promotes cell proliferation and
metastasis by influencing CXCL2 expression in HCC. Am J Transl Res.
7:2254–2261. 2015.PubMed/NCBI
|
|
14
|
Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan
J, Li Q, Zhang Y, Ding Y, Chen B and Chen L: MiR-141 suppresses the
migration and invasion of HCC cells by targeting Tiam1. PLoS One.
9:e883932014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao B, Gao K, Li L, Huang Z and Lin L:
miR-184 functions as an oncogenic regulator in hepatocellular
carcinoma (HCC). Biomed Pharmacother. 68:143–148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He J, Guo X, Sun L, Wang N and Bao J:
Regulatory network analysis of genes and microRNAs in human
hepatoblastoma. Oncol Lett. 12:4099–4106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cairo S, Wang Y, de Reyniès A, Duroure K,
Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM and
Buendia MA: Stem cell-like micro-RNA signature driven by Myc in
aggressive liver cancer. Proc Natl Acad Sci USA. 107:pp.
20471–20476. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen QG, Zhou W, Han T, Du SQ, Li ZH,
Zhang Z, Shan GY and Kong CZ: miR-378 suppresses prostate cancer
cell growth through downregulation of MAPK1 in vitro and in vivo.
Tumor Biol. 37:2095–2103. 2016. View Article : Google Scholar
|
|
19
|
Wei X, Li H, Zhang B, Li C, Dong D, Lan X,
Huang Y, Bai Y, Lin F, Zhao X and Chen H: miR-378a-3p promotes
differentiation and inhibits proliferation of myoblasts by
targeting HDAC4 in skeletal muscle development. RNA Biol.
13:1300–1309. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Li C, Li H, Song Y, Zhao Y, Zhai
L, Wang H, Zhong R, Tang H and Zhu D: miR-378 activates the
pyruvate-pep futile cycle and enhances lipolysis to ameliorate
obesity in mice. EBioMedicine. 5:93–104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
International Union Against Cancer (UICC),
. TNM classification of malignant tumors. Sobin LH, Gospodarowicz
MK and Wittekind Ch: 7th. Wiley-Blackwell; Oxford: 2010
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khare S, Zhang Q and Ibdah JA: Epigenetics
of hepatocellular carcinoma: Role of microRNA. World J
Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakao K, Miyaaki H and Ichikawa T:
Antitumor function of microRNA-122 against hepatocellular
carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu H, Wang G, Zhou X, Song X, Gao H, Ma
C, Chang H, Li H, Liu FF, Lu J and Ma J: miR-1299 suppresses cell
proliferation of hepatocellular carcinoma (HCC) by targeting CDK6.
Biomed Pharmacother. 83:792–797. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang CY, Huang XP, Zhu JY, Chen ZG, Li
XJ, Zhang XH, Huang S, He JB, Lian F, Zhao YN and Wu GB: miR-128-3p
suppresses hepatocellular carcinoma proliferation by regulating
PIK3R1 and is correlated with the prognosis of HCC patients. Oncol
Rep. 33:2889–2898. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang L, Li K and Guo T: miR-26a-5p
suppresses tumor metastasis by regulating EMT and is associated
with prognosis in HCC. Clin Transl Oncol. 19:695–703. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krist B, Florczyk U,
Pietraszek-Gremplewicz K, Józkowicz A and Dulak J: The role of
miR-378a in metabolism, angiogenesis, and muscle biology. Int J
Endocrinol. 2015:2817562015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang N, Wang J, Xie W, Lyu Q, Wu J, He J,
Qiu W, Xu N and Zhang Y: miR-378a-3p enhances adipogenesis by
targeting mitogen-activated protein kinase 1. Biochem Biophys Res
Commun. 457:37–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li H, Dai S, Zhen T, Shi H, Zhang F, Yang
Y, Kang L, Liang Y and Han A: Clinical and biological significance
of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur J Cancer.
50:1207–1221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Megiorni F, Cialfi S, McDowell HP, Felsani
A, Camero S, Guffanti A, Pizer B, Clerico A, De Grazia A, Pizzuti
A, et al: Deep Sequencing the microRNA profile in rhabdomyosarcoma
reveals down-regulation of miR-378 family members. BMC Cancer.
14:8802014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ikeda K, Horie-Inoue K, Ueno T, Suzuki T,
Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H and
Inoue S: miR-378a-3p modulates tamoxifen sensitivity in breast
cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 5:131702015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li C, Li Y, Lv H, Li S, Tang K, Zhou W, Yu
S and Chen X: The novel anti-neuroblastoma agent PF403, inhibits
proliferation and invasion in vitro and in brain xenografts. Int J
Oncol. 47:179–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao J, Liu X, Yang F, Liu T, Yan Q and
Yang X: By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM
inhibits breast cancer cell growth and metastasis. Oncotarget.
6:27187–27198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moreno L, Popov S, Jury A, Al Sarraj S,
Jones C and Zacharoulis S: Role of platelet derived growth factor
receptor (PDGFR) over-expression and angiogenesis in ependymoma. J
Neurooncol. 111:169–176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ghosh S, Sullivan CA, Zerkowski MP,
Molinaro AM, Rimm DL, Camp RL and Chung GG: High levels of vascular
endothelial growth factor and its receptors (VEGFR-1, VEGFR-2,
neuropilin-1) are associated with worse outcome in breast cancer.
Hum Pathol. 39:1835–1843. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burotto M, Chiou VL, Lee JM and Kohn EC:
The MAPK pathway across different malignancies: A new perspective.
Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song X, Wei Z and Shaikh ZA: Requirement
of ERα and basal activities of EGFR and Src kinase in Cd-induced
activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
Toxicol Appl Pharmacol. 287:26–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
